Breast mucinous carcinoma
diseaseOn this page
Also known as breast invasive mixed mucinous carcinomacolloid breast carcinomacolloid carcinoma of breastcolloid carcinoma of the breastinfiltrating colloid breast carcinomainfiltrating mucinous breast carcinomainvasive colloid breast carcinomainvasive mucinous breast carcinomamucinous breast cancermucinous breast carcinomamucinous carcinoma of breastmucinous carcinoma of the breast
Summary
Breast mucinous carcinoma (MONDO:0002707) is a cancer and 10 clinical trials. Top therapeutic interventions include carboplatin, epirubicin, and ferric carboxymaltose. A subtype of invasive ductal breast carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 10
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | breast mucinous carcinoma |
| Mondo ID | MONDO:0002707 |
| DOID | DOID:3610 |
| NCIT | C9131 |
| SNOMED CT | 444712000 |
| UMLS | C1334807 |
| MedGen | 235337 |
| Is cancer (heuristic) | yes |
Also known as: breast invasive mixed mucinous carcinoma · breast mucinous carcinoma · colloid breast carcinoma · colloid carcinoma of breast · colloid carcinoma of the breast · infiltrating colloid breast carcinoma · infiltrating mucinous breast carcinoma · invasive colloid breast carcinoma · invasive mucinous breast carcinoma · mucinous breast cancer · mucinous breast carcinoma · mucinous carcinoma of breast · mucinous carcinoma of the breast
Disease family
This is a subtype of invasive ductal breast carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › breast adenocarcinoma › breast ductal adenocarcinoma › invasive ductal breast carcinoma › breast mucinous carcinoma
Related subtypes (9): breast secretory carcinoma, glycogen-rich clear cell breast carcinoma, acinic cell breast carcinoma, invasive tubular breast carcinoma, scirrhous breast carcinoma, basal-like breast carcinoma, invasive ductal and lobular carcinoma, medullary breast carcinoma, pleomorphic breast carcinoma
Subtypes (1): breast columnar cell mucinous carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 10.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 4 |
| PHASE2 | 3 |
| PHASE2/PHASE3 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02221999 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients |
| NCT03201861 | PHASE3 | RECRUITING | Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women |
| NCT01426880 | PHASE2/PHASE3 | COMPLETED | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer |
| NCT01583426 | PHASE3 | COMPLETED | Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) |
| NCT02125344 | PHASE3 | COMPLETED | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) |
| NCT02879513 | PHASE3 | UNKNOWN | Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy |
| NCT01754519 | PHASE2 | TERMINATED | Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery |
| NCT02199418 | PHASE2 | COMPLETED | Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer |
| NCT02682693 | PHASE2 | COMPLETED | Denosumab as an add-on Neoadjuvant Treatment (GeparX) |
| NCT03602079 | PHASE1/PHASE2 | COMPLETED | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CARBOPLATIN | 4 | 3 |
| EPIRUBICIN | 4 | 2 |
| FERRIC CARBOXYMALTOSE | 4 | 1 |
| LETROZOLE | 4 | 1 |
| PERTUZUMAB | 4 | 1 |
| TRASTUZUMAB | 4 | 1 |
| TRASTUZUMAB BOTIDOTIN | 2 | 1 |
| ZENIDOLOL | 2 | 1 |